Recent Updates
Recently added Catalysts
NTLA

Intellia Therapeutics to Present at September Healthcare Investor Conferences

Key Takeaway: CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the following virtual
Price reaction · baseline $153.95 (2021-08-30 close) · hit after-hours · clean, no other NTLA news in the window
day 0 close · peak
+4.3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+76%
120-day peak, hindsight
Typical move
9.6%
average across 8 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
NTLA-2002
Phase 3 · Hereditary Angioedema

Full Press Release Details

CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the following virtual healthcare investor conferences in September:
Thursday, September 9, 2021
Wells Fargo Healthcare Conference
Monday, September 13, 2021
H.C. Wainwright 23rd Annual Global Investment Conference
A live webcast of Intellia’s presentations at these events will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Intellia’s website for approximately 14 days following each presentation.
About Intellia Therapeutics
Last updated: Aug 31, 2021